PRAVIN POTDAR - Academia.edu (original) (raw)

Papers by PRAVIN POTDAR

Journal of Cancer Science & Therapy, Jan 21, 2015

C ancer is developed due to the exposure of cells to various carcinogens which cause DNA damage a... more C ancer is developed due to the exposure of cells to various carcinogens which cause DNA damage as well as from genetic predisposition, where gene mutations are inherited from affected parents. Some forms of breast, colon and esophageal cancer are proved to be hereditary cancers and early detection of these cancers is very much essential. One of the main goals of cancer research is to identify molecules which are deregulated in the process of cancer development which can be used for early detection of cancer as well as to target cancer cells in vivo condition. These molecules are called biomarkers. The molecular biomarkers are mainly identified by using genomics, proteomics or imaging technologies such as PCR, Microarrays, FISH, etc. After completion of human genome project, the major challenge in oncology is to translate genetic information by advancement in several gene based technologies for diagnosis and management of various types of cancers. Recently, molecular profiling of tumor cells is also being used to determine specific types of malignancy. However, very few biomarkers are currently used as prognostic or predictive markers. Therefore, there is a great need to have a better understanding of new biomarkers of cancers and to translate them for use in early diagnosis and possible targeted therapies of cancers. This presentation will highlights most of the specific biomarkers which are presently used as a prognostic and predictive markers for breast, lung, colon, prostate, pancreatic and hematological cancers in human along with possible development in finding new biomarkers for better therapy. Biography Pravin D Potdar has completed his PhD from Cancer Research Institute, Tata Memorial Centre Mumbai in year 1991. He has worked as a Senior Scientist for 20 years at Cancer Research Institute (Present ACTRECT), and did extensive research on establishing Biomarkers for early detection of lung, breast and oral cancers. He has more than 30 years of research experience in the field of cellular and molecular biology of cancer and other genetic disorders. He was a Fellow of National Institute of Health (NIH), USA and also worked as a faculty at M.D. Anderson Cancer Centre, Houston, Texas, USA for 3 years. He is a recipient of prestigious National Cancer Institute, NIH, USA and a Birla Smarak Kosh, Mumbai awards for his contribution in cancer research. Presently, he is heading Department of Molecular Medicine & Biology at Jaslok Hospital & Research Centre, Mumbai for last 9 years. He has successfully sequenced BRCA1 and BRCA2 genes and Wilson Diseases gene in his laboratory and discovered specific novel mutations in Indian population. He is associated with many organizations and hold positions in their committees. He was honored with position of a Secretary for Scientific Advisory and Ethics Committee of Jaslok hospital for 5 years. He is presently "Vice President" of "Molecular Pathology Association of India (MPAI), upcoming organization in the field of Molecular Pathology. He has more than 50 publications in national & international journals, appointed as a reviewer for many national and international journals and attended several conferences, workshops

Journal of Cancer Science & Therapy, Jan 21, 2015

PubMed, 2012

Breast Cancer (BC) is a heterogeneous disease and arises from breast cancer initiating stem cell ... more Breast Cancer (BC) is a heterogeneous disease and arises from breast cancer initiating stem cell population in the tumor and these cells are resistant to cancer therapies. Thus identifying this cell type within the tumor clone is an important area of research to understand the mechanism of breast cancer development. Recently, our laboratory has isolated and characterized Human breast cancer mesenchymal stem cells (hBCMSCs) from human breast cancer and showed the heterogeneity of these cells existing in the tumor. Therefore, our present objective is to use this model system to identify, localize and define specific breast cancer initiating cells (BCICs) from the heterogeneous population of hBCMSCs cell line developed in our laboratory. Localization of specific cell types can be done by using specific cancer marker antibodies using Immunofluorescence microscopy. In this study we have used FITC labeled specific cancer antibodies i.e. p53, Rb1, Hras, Ki67, EGFR, GST, ETS1 and ATF2 to localize BCICs in this population of cells. Our results have demonstrated that few cells among many of the BC cells gave fluorescence with specific cancer antibody indicating that these cell types are BCICs that may be responsible for supporting the growth of other cell type to form tumors. The Phase Contrast Microscopy clearly showed giant cells with enlarged nucleus and scanty cytoplasm associated with many cytoplasmic granules. It also indicates that these cells are mainly responsible for supporting proliferation of surrounding cells that form a part of the BC tumor. We have further hypothesized that molecular profiling of these tumor cells will open a new avenue of molecular targeted therapies for Breast Cancer patients even at an advanced stage of disease.

PubMed, Sep 1, 1989

The present study reports light and electron microscopic observations of hamster cheek pouch epit... more The present study reports light and electron microscopic observations of hamster cheek pouch epithelium exposed to 25 micrograms DMBA (DMBA = 9,10 Dimethyl, 1,2 Benz(a)-nthracene, RA = Retinoic Acid) and 25 micrograms DMBA along with 25 micrograms, 50 micrograms and 100 micrograms retinoic acid. Significant delay in tumour induction was observed in the animals treated with DMBA + retinoic acid. DMBA + retinoic acid treated cheek pouch developed papillary epidermoid carcinomas which were less invasive and less keratinized than only DMBA treated animals. At cellular level DMBA treated animals showed keratinized cells with thick bundles of tonofilaments, broken basement membrane, wide intercellular spaces and loss of desmosomal attachments, whereas animals treated with DMBA + retinoic acid showed decrease in the intercellular spaces, maintenance of basement membrane and intracellular organelles with suppression of keratinization, indicating the differentiating effect of retinoic acid on DMBA transformed cells of hamster cheek pouch.

PubMed, 2010

Mesenchymal stem cells (MSCs), are multipotent stem cells that can differentiate into osteoblasts... more Mesenchymal stem cells (MSCs), are multipotent stem cells that can differentiate into osteoblasts, chondrocytes, myocytes and adipocytes. We utilized adipose tissue as our primary source, since it is a rich source of MSCs as well as it can be harvested using a minimally invasive surgical procedure. Both visceral and subcutaneous adipose tissue (VSAT, SCAT respectively) samples were cultured using growth medium without using any substratum for their attachment. We observed growth of mesenchymal like cells within 15 days of culturing. In spite of the absence of any substratum, the cells adhered to the bottom of the petri dish, and spread out within 2 hours. Presently VSAT cells have reached at passage 10 whereas; SCAT cells have reached at passage 14. Morphologically MSCs obtained from visceral adipose tissue were larger in shape than subcutaneous adipose tissue. We checked these cells for presence or absence of specific stem cell molecular markers. We found that VSAT and SCAT cells confirmed their MSC phenotype by expression of specific MSC markers CD 105 and CD 13 and absence of CD34 and CD 45 markers which are specific for haematopoietic stem cells. These cells also expressed SOX2 gene confirming their ability of self-renewal as well as expressed OCT4, LIF and NANOG for their properties for pluripotency & plasticity. Overall, it was shown that adipose tissue is a good source of mesenchymal stem cells. It was also shown that MSCs, isolated from adipose tissue are multipotent stem cells that can differentiate into osteoblasts, chondrocytes, cardiomyocytes, adipocytes and liver cells which may open a new era for cell based regenerative therapies for bone, cardiac and liver disorders.

Stem cell discovery, 2013

Development of Dermal cell line has great scope in the field of skin related diseases and regener... more Development of Dermal cell line has great scope in the field of skin related diseases and regenerative medicine. Alopecia leads to a skin disorder causing balding and its mechanism is not yet understood. In the present study, we have developed and characterized a heterogeneous population of human dermal mesenchymal-like stem cell line from scalp biopsy of androgenetic alopecia patient with a view to isolate cells from the bulge region of the hair follicle. Our study showed that the dermal cells isolated from dermis of skin showed epithelial-like cells expressing CD34 and Keratin 18, which are characteristic of bulge hair follicle cells. These cells also expressed mesenchymal phenotypes and pluripotency markers such as Oct4, Nanog and SOX 2. These cells were designated as "Human Dermal Mesenchymal-like Stem Cells (hDMSC s)". To confirm their epithelial phenotypes, we have grown these cells at low serum concentration and it was observed that 3% serum concentration provided optimum conditions for their growth and maintenance of characteristics. The hDMSCs cells are presently at passage 10. This study reports the establishment of human dermal mesenchymal-like cell line from the dermis of Alopecia patient, which may be used as an in vitro model system to study the mechanism of Alopecia and other related skin disorders.

Stem cell discovery, 2011

Breast cancer remains a leading cause of morbidity and mortality in women mainly because of the p... more Breast cancer remains a leading cause of morbidity and mortality in women mainly because of the propensity of primary breast tumors to metastasize. It is composed of heterogeneous cell populations with different biological properties. Breast cancer-initiating cells have been recently identified in breast carcinoma as CD44 + /CD24 −/low cells, which display stem cell like properties. In the present study, we have isolated breast cancer stem cells from non-metastasis tumor tissue, which is presently at passage 18 and designated as human Breast Cancer Mesenchymal Stem Cells (hBCMSCs) line. These cells showed spindle shaped morphology and formed mammospheres as well as pluripotency clones indicating their stem cell nature. Molecular marker study confirmed mesenchymal nature as well as pluripotency, plasticity and oncogenicity of these cells. The hBCMSCs cell line may likely contain a heterogeneous population of malignant cells. Interestingly, we also found that these cells exhibit BRCA 2 mutation, which was found in Indian population. Overall, this study revealed that hBCMSCs cell line may represent a suitable in vitro model to study the mechanism of breast cancer which further leads to an identification of molecular targets for future breast cancer targeted therapy.

Cell, stem cells and regenerative medicine, 2015

Chronic Myeloid leukemia (CML) is a disorder causing uncontrolled growth of myeloproliferative bl... more Chronic Myeloid leukemia (CML) is a disorder causing uncontrolled growth of myeloproliferative blast cells. Tyrosine kinase inhibitors are not really useful in advanced stages and have their own side effects, reactions and resistance as well. Till date, CML can be fully cured only by bone marrow transplantation (BMT) which has its own limitations and thus need further studies to increase better survival of CML patients by this procedure. Our lab at Jaslok Hospital has been working on studying and characterizing mesenchymal stem cells in various types of hematological malignancies. We came up with a concept of isolating and characterizing mesenchymal stem cells (MSCs) from peripheral blood of a CML patient which can be used in combination with Bone Marrow Transplantation in the same CML patient. Our study has shown that the stem cells derived from peripheral blood of CML patient were found to be BCR/ABL-ve. We designated this cell line as a "BCR/ABL-ve " cell line. Molecular characterization of these cells further confirmed their Mesenchymal phenotypes with distinct expression of CD105, CD13 and CD73 genes. Interestingly these cells also expressed pluripotency genes such as OCT4 and NANOG and cytokines i.e. IL6 and TNFα. We further confirmed the normal phenotype of BCR/ABL-ve MSCs by localizing expression of H-Ras, Rb, P53, P16, P21, and EGFR and Ki67 cancer related proteins in these cells by immunofluorescence Microscopy and by in vitro transformation assay. Thus, we suggest that these normal BCR/ABL-ve MSCs derived from CML patient's peripheral blood can be used in addition to BMT procedure for a better recovery of CML disease in near future.

Diseases & research, 2023

Journal of Cancer Science & Therapy, Jul 23, 2015

B esides being the most common cancer in men, prostate cancer is heavily debated because of patie... more B esides being the most common cancer in men, prostate cancer is heavily debated because of patient management issues. Since the adoption of PSA testing for routine screening and diagnostic purposes, many men have been diagnosed through the use of this molecular marker, however, at the cost of over-diagnosis and over-treatment. Recent reports of the PLCO (US) and ERSPC (Europe) trials indicate that prostate cancer screening by means of PSA has only a modest effect on mortality. However, men in the control group could still have undergone a PSA test that eventually led to the prostate cancer diagnosis. Strikingly, but not unexpected, over 75% of all the biopsies were false positive and of those men that were identified with prostate cancer, the majority were early stage (I or II) and low Gleason score (6). Epigenetics in general and DNA methylation in particular has been shown to play a crucial role in the onset and progression of cancer. DNA-methylation biomarkers are actively used to improve patient management and avoid unnecessary repeat biopsies and potential over-treatment of patients. The utility of DNA-methylation markers goes much further and could eventually find application in predicting which men are at increased risk of harboring occult cancer whether a man has aggressive cancer or whether he could go on to active surveillance or such markers could be used for early stage screening purposes in non-invasive sources. A single marker or set of markers is unlikely to result in an absolutely correct prediction. Hence, the most optimal solution would be to combine the strengths of different types of markers and to strive for the largest complementarity and synergy. The relative weight of the markers can be done based on their individual and proven value as interpreted by experts or this could be mathematically modeled leading to a more uniform decision making process and better patient management.

Journal of Cancer Science & Therapy, Aug 18, 2015

Molecular Cancer

Lung cancer is the primary cause of mortality in the United States and around the globe. Therapeu... more Lung cancer is the primary cause of mortality in the United States and around the globe. Therapeutic options for lung cancer treatment include surgery, radiation therapy, chemotherapy, and targeted drug therapy. Medical management is often associated with the development of treatment resistance leading to relapse. Immunotherapy is profoundly altering the approach to cancer treatment owing to its tolerable safety profile, sustained therapeutic response due to immunological memory generation, and effectiveness across a broad patient population. Different tumor-specific vaccination strategies are gaining ground in the treatment of lung cancer. Recent advances in adoptive cell therapy (CAR T, TCR, TIL), the associated clinical trials on lung cancer, and associated hurdles are discussed in this review. Recent trials on lung cancer patients (without a targetable oncogenic driver alteration) reveal significant and sustained responses when treated with programmed death-1/programmed death-li...

Materials Today Communications

Journal of Oncology Translational Research, 2020

Cell & developmental biology, 2020

Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduct... more Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Decellularized goat-lung scaffold was fabricated by removing cells from cadaver goat-lung tissue, and the scaffold was modified with chitosan/nanohydroxyapatite composite for the purpose of bone tissue engineering applications. MTT assay with osteoblasts, seeded over the chitosan/nanohydroxyapatite-modified decellularized scaffold, demonstrated significantly higher cell growth as compared to the decellularized scaffold without modification. SEM analysis of cell-seeded scaffold, after incubation for 7 days, represented a good cell adhesion, and the cells spread over the chitosan/nanohydroxyapatite-modified decellularized scaffold. Expression of bone-tissue-specific osteocalcin gene in the osteoblast cells grown over the chitosan/nanohydroxyapatite-modified decellularized scaffold clearly signifies that the cellsmaintained th...

Journal of Cancer Science & Therapy, Jan 21, 2015

C ancer is developed due to the exposure of cells to various carcinogens which cause DNA damage a... more C ancer is developed due to the exposure of cells to various carcinogens which cause DNA damage as well as from genetic predisposition, where gene mutations are inherited from affected parents. Some forms of breast, colon and esophageal cancer are proved to be hereditary cancers and early detection of these cancers is very much essential. One of the main goals of cancer research is to identify molecules which are deregulated in the process of cancer development which can be used for early detection of cancer as well as to target cancer cells in vivo condition. These molecules are called biomarkers. The molecular biomarkers are mainly identified by using genomics, proteomics or imaging technologies such as PCR, Microarrays, FISH, etc. After completion of human genome project, the major challenge in oncology is to translate genetic information by advancement in several gene based technologies for diagnosis and management of various types of cancers. Recently, molecular profiling of tumor cells is also being used to determine specific types of malignancy. However, very few biomarkers are currently used as prognostic or predictive markers. Therefore, there is a great need to have a better understanding of new biomarkers of cancers and to translate them for use in early diagnosis and possible targeted therapies of cancers. This presentation will highlights most of the specific biomarkers which are presently used as a prognostic and predictive markers for breast, lung, colon, prostate, pancreatic and hematological cancers in human along with possible development in finding new biomarkers for better therapy. Biography Pravin D Potdar has completed his PhD from Cancer Research Institute, Tata Memorial Centre Mumbai in year 1991. He has worked as a Senior Scientist for 20 years at Cancer Research Institute (Present ACTRECT), and did extensive research on establishing Biomarkers for early detection of lung, breast and oral cancers. He has more than 30 years of research experience in the field of cellular and molecular biology of cancer and other genetic disorders. He was a Fellow of National Institute of Health (NIH), USA and also worked as a faculty at M.D. Anderson Cancer Centre, Houston, Texas, USA for 3 years. He is a recipient of prestigious National Cancer Institute, NIH, USA and a Birla Smarak Kosh, Mumbai awards for his contribution in cancer research. Presently, he is heading Department of Molecular Medicine & Biology at Jaslok Hospital & Research Centre, Mumbai for last 9 years. He has successfully sequenced BRCA1 and BRCA2 genes and Wilson Diseases gene in his laboratory and discovered specific novel mutations in Indian population. He is associated with many organizations and hold positions in their committees. He was honored with position of a Secretary for Scientific Advisory and Ethics Committee of Jaslok hospital for 5 years. He is presently "Vice President" of "Molecular Pathology Association of India (MPAI), upcoming organization in the field of Molecular Pathology. He has more than 50 publications in national & international journals, appointed as a reviewer for many national and international journals and attended several conferences, workshops

Journal of Cancer Science & Therapy, Jan 21, 2015

PubMed, 2012

Breast Cancer (BC) is a heterogeneous disease and arises from breast cancer initiating stem cell ... more Breast Cancer (BC) is a heterogeneous disease and arises from breast cancer initiating stem cell population in the tumor and these cells are resistant to cancer therapies. Thus identifying this cell type within the tumor clone is an important area of research to understand the mechanism of breast cancer development. Recently, our laboratory has isolated and characterized Human breast cancer mesenchymal stem cells (hBCMSCs) from human breast cancer and showed the heterogeneity of these cells existing in the tumor. Therefore, our present objective is to use this model system to identify, localize and define specific breast cancer initiating cells (BCICs) from the heterogeneous population of hBCMSCs cell line developed in our laboratory. Localization of specific cell types can be done by using specific cancer marker antibodies using Immunofluorescence microscopy. In this study we have used FITC labeled specific cancer antibodies i.e. p53, Rb1, Hras, Ki67, EGFR, GST, ETS1 and ATF2 to localize BCICs in this population of cells. Our results have demonstrated that few cells among many of the BC cells gave fluorescence with specific cancer antibody indicating that these cell types are BCICs that may be responsible for supporting the growth of other cell type to form tumors. The Phase Contrast Microscopy clearly showed giant cells with enlarged nucleus and scanty cytoplasm associated with many cytoplasmic granules. It also indicates that these cells are mainly responsible for supporting proliferation of surrounding cells that form a part of the BC tumor. We have further hypothesized that molecular profiling of these tumor cells will open a new avenue of molecular targeted therapies for Breast Cancer patients even at an advanced stage of disease.

PubMed, Sep 1, 1989

The present study reports light and electron microscopic observations of hamster cheek pouch epit... more The present study reports light and electron microscopic observations of hamster cheek pouch epithelium exposed to 25 micrograms DMBA (DMBA = 9,10 Dimethyl, 1,2 Benz(a)-nthracene, RA = Retinoic Acid) and 25 micrograms DMBA along with 25 micrograms, 50 micrograms and 100 micrograms retinoic acid. Significant delay in tumour induction was observed in the animals treated with DMBA + retinoic acid. DMBA + retinoic acid treated cheek pouch developed papillary epidermoid carcinomas which were less invasive and less keratinized than only DMBA treated animals. At cellular level DMBA treated animals showed keratinized cells with thick bundles of tonofilaments, broken basement membrane, wide intercellular spaces and loss of desmosomal attachments, whereas animals treated with DMBA + retinoic acid showed decrease in the intercellular spaces, maintenance of basement membrane and intracellular organelles with suppression of keratinization, indicating the differentiating effect of retinoic acid on DMBA transformed cells of hamster cheek pouch.

PubMed, 2010

Mesenchymal stem cells (MSCs), are multipotent stem cells that can differentiate into osteoblasts... more Mesenchymal stem cells (MSCs), are multipotent stem cells that can differentiate into osteoblasts, chondrocytes, myocytes and adipocytes. We utilized adipose tissue as our primary source, since it is a rich source of MSCs as well as it can be harvested using a minimally invasive surgical procedure. Both visceral and subcutaneous adipose tissue (VSAT, SCAT respectively) samples were cultured using growth medium without using any substratum for their attachment. We observed growth of mesenchymal like cells within 15 days of culturing. In spite of the absence of any substratum, the cells adhered to the bottom of the petri dish, and spread out within 2 hours. Presently VSAT cells have reached at passage 10 whereas; SCAT cells have reached at passage 14. Morphologically MSCs obtained from visceral adipose tissue were larger in shape than subcutaneous adipose tissue. We checked these cells for presence or absence of specific stem cell molecular markers. We found that VSAT and SCAT cells confirmed their MSC phenotype by expression of specific MSC markers CD 105 and CD 13 and absence of CD34 and CD 45 markers which are specific for haematopoietic stem cells. These cells also expressed SOX2 gene confirming their ability of self-renewal as well as expressed OCT4, LIF and NANOG for their properties for pluripotency & plasticity. Overall, it was shown that adipose tissue is a good source of mesenchymal stem cells. It was also shown that MSCs, isolated from adipose tissue are multipotent stem cells that can differentiate into osteoblasts, chondrocytes, cardiomyocytes, adipocytes and liver cells which may open a new era for cell based regenerative therapies for bone, cardiac and liver disorders.

Stem cell discovery, 2013

Development of Dermal cell line has great scope in the field of skin related diseases and regener... more Development of Dermal cell line has great scope in the field of skin related diseases and regenerative medicine. Alopecia leads to a skin disorder causing balding and its mechanism is not yet understood. In the present study, we have developed and characterized a heterogeneous population of human dermal mesenchymal-like stem cell line from scalp biopsy of androgenetic alopecia patient with a view to isolate cells from the bulge region of the hair follicle. Our study showed that the dermal cells isolated from dermis of skin showed epithelial-like cells expressing CD34 and Keratin 18, which are characteristic of bulge hair follicle cells. These cells also expressed mesenchymal phenotypes and pluripotency markers such as Oct4, Nanog and SOX 2. These cells were designated as "Human Dermal Mesenchymal-like Stem Cells (hDMSC s)". To confirm their epithelial phenotypes, we have grown these cells at low serum concentration and it was observed that 3% serum concentration provided optimum conditions for their growth and maintenance of characteristics. The hDMSCs cells are presently at passage 10. This study reports the establishment of human dermal mesenchymal-like cell line from the dermis of Alopecia patient, which may be used as an in vitro model system to study the mechanism of Alopecia and other related skin disorders.

Stem cell discovery, 2011

Breast cancer remains a leading cause of morbidity and mortality in women mainly because of the p... more Breast cancer remains a leading cause of morbidity and mortality in women mainly because of the propensity of primary breast tumors to metastasize. It is composed of heterogeneous cell populations with different biological properties. Breast cancer-initiating cells have been recently identified in breast carcinoma as CD44 + /CD24 −/low cells, which display stem cell like properties. In the present study, we have isolated breast cancer stem cells from non-metastasis tumor tissue, which is presently at passage 18 and designated as human Breast Cancer Mesenchymal Stem Cells (hBCMSCs) line. These cells showed spindle shaped morphology and formed mammospheres as well as pluripotency clones indicating their stem cell nature. Molecular marker study confirmed mesenchymal nature as well as pluripotency, plasticity and oncogenicity of these cells. The hBCMSCs cell line may likely contain a heterogeneous population of malignant cells. Interestingly, we also found that these cells exhibit BRCA 2 mutation, which was found in Indian population. Overall, this study revealed that hBCMSCs cell line may represent a suitable in vitro model to study the mechanism of breast cancer which further leads to an identification of molecular targets for future breast cancer targeted therapy.

Cell, stem cells and regenerative medicine, 2015

Chronic Myeloid leukemia (CML) is a disorder causing uncontrolled growth of myeloproliferative bl... more Chronic Myeloid leukemia (CML) is a disorder causing uncontrolled growth of myeloproliferative blast cells. Tyrosine kinase inhibitors are not really useful in advanced stages and have their own side effects, reactions and resistance as well. Till date, CML can be fully cured only by bone marrow transplantation (BMT) which has its own limitations and thus need further studies to increase better survival of CML patients by this procedure. Our lab at Jaslok Hospital has been working on studying and characterizing mesenchymal stem cells in various types of hematological malignancies. We came up with a concept of isolating and characterizing mesenchymal stem cells (MSCs) from peripheral blood of a CML patient which can be used in combination with Bone Marrow Transplantation in the same CML patient. Our study has shown that the stem cells derived from peripheral blood of CML patient were found to be BCR/ABL-ve. We designated this cell line as a "BCR/ABL-ve " cell line. Molecular characterization of these cells further confirmed their Mesenchymal phenotypes with distinct expression of CD105, CD13 and CD73 genes. Interestingly these cells also expressed pluripotency genes such as OCT4 and NANOG and cytokines i.e. IL6 and TNFα. We further confirmed the normal phenotype of BCR/ABL-ve MSCs by localizing expression of H-Ras, Rb, P53, P16, P21, and EGFR and Ki67 cancer related proteins in these cells by immunofluorescence Microscopy and by in vitro transformation assay. Thus, we suggest that these normal BCR/ABL-ve MSCs derived from CML patient's peripheral blood can be used in addition to BMT procedure for a better recovery of CML disease in near future.

Diseases & research, 2023

Journal of Cancer Science & Therapy, Jul 23, 2015

B esides being the most common cancer in men, prostate cancer is heavily debated because of patie... more B esides being the most common cancer in men, prostate cancer is heavily debated because of patient management issues. Since the adoption of PSA testing for routine screening and diagnostic purposes, many men have been diagnosed through the use of this molecular marker, however, at the cost of over-diagnosis and over-treatment. Recent reports of the PLCO (US) and ERSPC (Europe) trials indicate that prostate cancer screening by means of PSA has only a modest effect on mortality. However, men in the control group could still have undergone a PSA test that eventually led to the prostate cancer diagnosis. Strikingly, but not unexpected, over 75% of all the biopsies were false positive and of those men that were identified with prostate cancer, the majority were early stage (I or II) and low Gleason score (6). Epigenetics in general and DNA methylation in particular has been shown to play a crucial role in the onset and progression of cancer. DNA-methylation biomarkers are actively used to improve patient management and avoid unnecessary repeat biopsies and potential over-treatment of patients. The utility of DNA-methylation markers goes much further and could eventually find application in predicting which men are at increased risk of harboring occult cancer whether a man has aggressive cancer or whether he could go on to active surveillance or such markers could be used for early stage screening purposes in non-invasive sources. A single marker or set of markers is unlikely to result in an absolutely correct prediction. Hence, the most optimal solution would be to combine the strengths of different types of markers and to strive for the largest complementarity and synergy. The relative weight of the markers can be done based on their individual and proven value as interpreted by experts or this could be mathematically modeled leading to a more uniform decision making process and better patient management.

Journal of Cancer Science & Therapy, Aug 18, 2015

Molecular Cancer

Lung cancer is the primary cause of mortality in the United States and around the globe. Therapeu... more Lung cancer is the primary cause of mortality in the United States and around the globe. Therapeutic options for lung cancer treatment include surgery, radiation therapy, chemotherapy, and targeted drug therapy. Medical management is often associated with the development of treatment resistance leading to relapse. Immunotherapy is profoundly altering the approach to cancer treatment owing to its tolerable safety profile, sustained therapeutic response due to immunological memory generation, and effectiveness across a broad patient population. Different tumor-specific vaccination strategies are gaining ground in the treatment of lung cancer. Recent advances in adoptive cell therapy (CAR T, TCR, TIL), the associated clinical trials on lung cancer, and associated hurdles are discussed in this review. Recent trials on lung cancer patients (without a targetable oncogenic driver alteration) reveal significant and sustained responses when treated with programmed death-1/programmed death-li...

Materials Today Communications

Journal of Oncology Translational Research, 2020

Cell & developmental biology, 2020

Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduct... more Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Decellularized goat-lung scaffold was fabricated by removing cells from cadaver goat-lung tissue, and the scaffold was modified with chitosan/nanohydroxyapatite composite for the purpose of bone tissue engineering applications. MTT assay with osteoblasts, seeded over the chitosan/nanohydroxyapatite-modified decellularized scaffold, demonstrated significantly higher cell growth as compared to the decellularized scaffold without modification. SEM analysis of cell-seeded scaffold, after incubation for 7 days, represented a good cell adhesion, and the cells spread over the chitosan/nanohydroxyapatite-modified decellularized scaffold. Expression of bone-tissue-specific osteocalcin gene in the osteoblast cells grown over the chitosan/nanohydroxyapatite-modified decellularized scaffold clearly signifies that the cellsmaintained th...